AR098417A1 - Formulación farmacéutica combinada que comprende amlodipina, losartán y rosuvastatina - Google Patents
Formulación farmacéutica combinada que comprende amlodipina, losartán y rosuvastatinaInfo
- Publication number
- AR098417A1 AR098417A1 ARP140104281A ARP140104281A AR098417A1 AR 098417 A1 AR098417 A1 AR 098417A1 AR P140104281 A ARP140104281 A AR P140104281A AR P140104281 A ARP140104281 A AR P140104281A AR 098417 A1 AR098417 A1 AR 098417A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- rosuvastatin
- losartan
- combined
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 abstract 13
- 239000002083 C09CA01 - Losartan Substances 0.000 abstract 5
- 239000000654 additive Substances 0.000 abstract 5
- 230000000996 additive effect Effects 0.000 abstract 5
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 5
- 238000009472 formulation Methods 0.000 abstract 5
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 abstract 5
- 229960004773 losartan Drugs 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 5
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 abstract 5
- 229960000672 rosuvastatin Drugs 0.000 abstract 5
- 229960000528 amlodipine Drugs 0.000 abstract 4
- 239000012458 free base Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una formulación farmacéutica combinada, que comprende: (1) una primera, parte discreta que comprende amlodipina o una de sus sales farmacéuticamente aceptables, rosuvastatina o una de sus sales farmacéuticamente aceptables y un aditivo farmacéuticamente aceptable; y (2) una segunda parte discreta que comprende losartán o una de sus sales farmacéuticamente aceptables y un aditivo farmacéuticamente aceptable, donde dichas partes discretas están físicamente separadas entre sí. Reivindicación 2: La formulación farmacéutica combinada de la reivindicación 1, donde la formulación combinada se presenta en la forma de un comprimido bicapa que comprende: (1) una primera capa que comprende amlodipina o una de sus sales farmacéuticamente aceptables, rosuvastatina o una de sus sales farmacéuticamente aceptables y un aditivo farmacéuticamente aceptable; y (2) una segunda capa que comprende losartán o una de sus sales farmacéuticamente aceptables y un aditivo farmacéuticamente aceptable. Reivindicación 8: La formulación combinada de dosis fija de la reivindicación 7, donde la cantidad de amlodipina o una de sus sales farmacéuticamente aceptables, convertida a la forma de base libre de amlodipina, es de 5 a 10 mg. Reivindicación 9: La formulación combinada de dosis fija de la reivindicación 7, donde la cantidad de rosuvastatina o una de sus sales farmacéuticamente aceptables, convertida a la forma de base libre de rosuvastatina, es de 10 a 20 mg. Reivindicación 10: La formulación combinada de dosis fija de la reivindicación 7, donde la cantidad de losartán o una de sus sales farmacéuticamente aceptables, convertida a la forma de base libre de losartán, es de 45 a 100 mg. Reivindicación 11: Un método para preparar una formulación farmacéutica combinada, que comprende los pasos de: a) mezclar amlodipina o una de sus sales farmacéuticamente aceptables, rosuvastatina o una de sus sales farmacéuticamente y un aditivo farmacéuticamente aceptable; b) mezclar losartán o una de sus sales farmacéuticamente aceptables y una de sus sales farmacéuticamente aceptables; y c) cargar una parte discreta preparada en el paso a) y una parte discreta preparada en el paso b) en una formulación, donde dichas partes discretas están físicamente separadas entre sí.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130147883A KR101910901B1 (ko) | 2013-11-29 | 2013-11-29 | 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098417A1 true AR098417A1 (es) | 2016-05-26 |
Family
ID=53199333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104281A AR098417A1 (es) | 2013-11-29 | 2014-11-14 | Formulación farmacéutica combinada que comprende amlodipina, losartán y rosuvastatina |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9833413B2 (es) |
| EP (1) | EP3073998A4 (es) |
| JP (1) | JP6427572B2 (es) |
| KR (1) | KR101910901B1 (es) |
| CN (1) | CN105792813B (es) |
| AR (1) | AR098417A1 (es) |
| AU (1) | AU2014354475B2 (es) |
| BR (1) | BR112016011603A2 (es) |
| CA (1) | CA2929862A1 (es) |
| CL (1) | CL2016001298A1 (es) |
| JO (1) | JO3557B1 (es) |
| MX (1) | MX370041B (es) |
| PH (1) | PH12016500833A1 (es) |
| RU (1) | RU2660586C1 (es) |
| SA (1) | SA516371218B1 (es) |
| TW (1) | TWI649099B (es) |
| UA (1) | UA120043C2 (es) |
| UY (1) | UY35859A (es) |
| WO (1) | WO2015080433A1 (es) |
| ZA (1) | ZA201603272B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017014311A (es) * | 2015-06-30 | 2018-03-07 | Hanmi Pharm Ind Co Ltd | Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina. |
| EP3320903B1 (en) * | 2015-07-08 | 2021-05-19 | HK inno.N Corporation | Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin |
| CR20190265A (es) * | 2016-11-15 | 2019-08-22 | Hanmi Pharm Ind Co Ltd | Preparación de un complejo farmacéutico que comprende amlodipina, losartán y rosuvastatina |
| KR101920996B1 (ko) * | 2017-04-26 | 2018-11-22 | 알보젠코리아 주식회사 | HMG-CoA 환원효소 저해제 및 칼슘채널 차단제를 포함하는 복합제제 |
| KR20190043076A (ko) * | 2017-10-17 | 2019-04-25 | 한미약품 주식회사 | 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제 |
| KR101997652B1 (ko) * | 2018-01-22 | 2019-07-08 | 보령제약 주식회사 | 약학적 제제 |
| KR102569271B1 (ko) * | 2018-03-19 | 2023-08-23 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 약제학적 복합제제 |
| KR102108396B1 (ko) * | 2018-04-25 | 2020-05-07 | 제일약품주식회사 | 약학적 제제 |
| KR101992400B1 (ko) * | 2018-04-30 | 2019-06-24 | 보령제약 주식회사 | 약학적 제제 |
| KR102500643B1 (ko) * | 2019-04-18 | 2023-02-16 | 한미약품 주식회사 | 에제티미브 및 로사르탄을 포함하는 약제학적 복합제제 |
| KR102608889B1 (ko) * | 2020-07-14 | 2023-12-04 | 한미약품 주식회사 | 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법 |
| KR20220026641A (ko) * | 2020-08-25 | 2022-03-07 | 주식회사 대웅제약 | 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물 |
| EP4245298A1 (en) * | 2020-12-18 | 2023-09-20 | Daewoong Pharmaceutical Co., Ltd. | Novel formulation for oral administration, comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5138069A (en) | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
| WO1995017396A1 (en) | 1993-12-23 | 1995-06-29 | Merck & Co., Inc. | Polymorphs of losartan and the process for the preparation of form ii of losartan |
| EP1314425A4 (en) * | 2000-08-30 | 2004-06-02 | Sankyo Co | MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE |
| KR100452491B1 (ko) | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 |
| CN103083318A (zh) * | 2004-11-05 | 2013-05-08 | 贝林格尔.英格海姆国际有限公司 | 包含替米沙坦和氨氯地平的双层片剂 |
| KR101247583B1 (ko) * | 2006-12-08 | 2013-03-26 | 한미사이언스 주식회사 | 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물 |
| CA2677623C (en) * | 2007-02-09 | 2015-04-07 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
| US20090093542A1 (en) * | 2007-10-04 | 2009-04-09 | Cooper Garth J S | Copper antagonist compositions |
| WO2009154810A2 (en) * | 2008-02-25 | 2009-12-23 | Dr. Reddy's Laboratories Ltd. | Delivery systems for multiple active agents |
| CN101632672B (zh) * | 2008-07-24 | 2011-01-12 | 鲁南制药集团股份有限公司 | 一种用于治疗高血压的复方药物组合物 |
| UA102721C2 (uk) * | 2009-01-23 | 2013-08-12 | Ханми Сайенс Ко., Лтд. | Тверда фармацевтична композиція, яка містить амлодипін і лозартан, і спосіб її отримання |
| CN101690816A (zh) * | 2009-08-16 | 2010-04-07 | 王丽燕 | 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物 |
| CN101637609A (zh) * | 2009-09-06 | 2010-02-03 | 王丽燕 | 含氨氯地平、aⅱ受体拮抗剂和他汀类药的药物组合物 |
| WO2011152803A1 (en) * | 2010-06-03 | 2011-12-08 | Mahmut Bilgic | Water soluble formulation comprising a combination of amlodipine and a statin |
| KR101907881B1 (ko) * | 2011-12-30 | 2018-12-11 | 한미약품 주식회사 | 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형 |
| KR101378973B1 (ko) * | 2012-04-13 | 2014-03-28 | 한미약품 주식회사 | 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법 |
-
2013
- 2013-11-29 KR KR1020130147883A patent/KR101910901B1/ko active IP Right Grant
-
2014
- 2014-11-14 AR ARP140104281A patent/AR098417A1/es not_active Application Discontinuation
- 2014-11-20 US US15/039,238 patent/US9833413B2/en active Active
- 2014-11-20 RU RU2016125749A patent/RU2660586C1/ru active
- 2014-11-20 EP EP14866739.7A patent/EP3073998A4/en not_active Withdrawn
- 2014-11-20 CA CA2929862A patent/CA2929862A1/en not_active Abandoned
- 2014-11-20 UA UAA201606918A patent/UA120043C2/uk unknown
- 2014-11-20 CN CN201480064825.8A patent/CN105792813B/zh active Active
- 2014-11-20 WO PCT/KR2014/011205 patent/WO2015080433A1/en active Application Filing
- 2014-11-20 BR BR112016011603A patent/BR112016011603A2/pt not_active IP Right Cessation
- 2014-11-20 MX MX2016006415A patent/MX370041B/es active IP Right Grant
- 2014-11-20 AU AU2014354475A patent/AU2014354475B2/en not_active Ceased
- 2014-11-20 JP JP2016531655A patent/JP6427572B2/ja not_active Expired - Fee Related
- 2014-11-27 JO JOP/2014/0340A patent/JO3557B1/ar active
- 2014-11-28 UY UY0001035859A patent/UY35859A/es not_active Application Discontinuation
- 2014-11-28 TW TW103141429A patent/TWI649099B/zh active
-
2016
- 2016-05-05 PH PH12016500833A patent/PH12016500833A1/en unknown
- 2016-05-13 ZA ZA2016/03272A patent/ZA201603272B/en unknown
- 2016-05-26 SA SA516371218A patent/SA516371218B1/ar unknown
- 2016-05-27 CL CL2016001298A patent/CL2016001298A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201609198A (zh) | 2016-03-16 |
| UY35859A (es) | 2015-06-30 |
| RU2660586C1 (ru) | 2018-07-06 |
| JO3557B1 (ar) | 2020-07-05 |
| CA2929862A1 (en) | 2015-06-04 |
| US9833413B2 (en) | 2017-12-05 |
| MX370041B (es) | 2019-11-29 |
| US20170027871A1 (en) | 2017-02-02 |
| UA120043C2 (uk) | 2019-09-25 |
| WO2015080433A1 (en) | 2015-06-04 |
| EP3073998A4 (en) | 2017-05-31 |
| CN105792813A (zh) | 2016-07-20 |
| KR101910901B1 (ko) | 2018-10-24 |
| PH12016500833A1 (en) | 2016-06-13 |
| JP2017501126A (ja) | 2017-01-12 |
| JP6427572B2 (ja) | 2018-11-21 |
| SA516371218B1 (ar) | 2017-12-21 |
| EP3073998A1 (en) | 2016-10-05 |
| CL2016001298A1 (es) | 2017-01-06 |
| BR112016011603A2 (pt) | 2022-07-12 |
| KR20150067777A (ko) | 2015-06-19 |
| AU2014354475B2 (en) | 2019-12-19 |
| MX2016006415A (es) | 2016-07-19 |
| ZA201603272B (en) | 2018-08-29 |
| CN105792813B (zh) | 2019-11-19 |
| TWI649099B (zh) | 2019-02-01 |
| AU2014354475A1 (en) | 2016-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098417A1 (es) | Formulación farmacéutica combinada que comprende amlodipina, losartán y rosuvastatina | |
| CY1123122T1 (el) | Σκευασμα ντοξυλαμινης και πυριδοξινης ή/και μεταβολιτων ή αλατων αυτων | |
| CL2014001450A1 (es) | Forma de dosis de liberacion controlada solida que comprende un analgesico opioide dispersado en un material de matriz; metodo de preparacion; uso en el tratamiento del dolor. | |
| EA201490014A1 (ru) | Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот | |
| CO2019007888A2 (es) | Inhibidores selectivos de jak1 | |
| EA201071204A1 (ru) | Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности | |
| CL2016002560A1 (es) | Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación. | |
| AR088232A1 (es) | Composiciones farmaceuticas | |
| CO6592025A2 (es) | Fomulación farmacéutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg -coa recutasa e irbesartan | |
| GT201500035A (es) | Composición farmacéutica oral en forma de microesferas y proceso de elaboración | |
| AR092356A1 (es) | Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion | |
| AR105758A1 (es) | Formulación farmacéutica compleja que comprende amlodipina, losartan y clortalidona | |
| AR096725A1 (es) | Formulación de comprimidos masticables que comprende tadalafil o una de sus sales aceptables desde el punto de vista farmacéutico | |
| BR112016005361A8 (pt) | inibidores de girase tricíclica, composição, forma de dosagem, embalagem e dispositivo dispensador que os compreende, bem como uso dos mesmos | |
| CL2013003176A1 (es) | Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol. | |
| AR104185A1 (es) | Formulaciones farmacéuticas | |
| AR097202A1 (es) | Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa | |
| ECSP12012329A (es) | Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmacéuticas que la contienen | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| TR201815617A2 (tr) | Deksketoprofen içeren bir formülasyon. | |
| PE20150935A1 (es) | Formulacion de comprimido compuesto de dos capas que comprende atorvastatina, irbesartan y carbonato de magnesio | |
| DOP2021000052A (es) | Procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina | |
| ES2502140T1 (es) | Comprimidos de liberación inmediata de rasagilina hemitartrato | |
| UY36958A (es) | Compuestos para administración intracelular | |
| ES2436344B1 (es) | Composición farmacéutica de diacetilmorfina y naloxona para administración oral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |